How many times should I follow up with a Founder (long time no contact)?

If a mutual offered the intro, send it while their permission is fresh. Send when you have a real trigger: news, a useful artifact, a role change, a season. After that, send a breakup note and archive it. A founder who wants it will answer a clean close more often than a fifth bump.

How do I introduce myself without sounding stiff?

Use one sentence for who you help and one sentence for why now. Skip the origin story. If a mutual is involved, put their name near the top so the email has a human reason to exist. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it weird to email someone after six months of silence?

Not if you have a new reason and you don't pretend the old thread is still warm. Lead with the trigger, remind them who you are in one line, and make the ask optional. Nostalgia without news is just another cold email with extra steps.

Is it okay to send this introduction on LinkedIn instead of email?

Yes if this founder is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals introduction?

Don't use consumer-startup slang. It's a credibility leak. Calling them a 'decision maker' or pitching like they're a Fortune 500 process. Don't open with 'it's been a while' and then paste the old pitch. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Pharmaceuticals · Founder · Long Time No Contact

Introduction for Pharmaceuticals Founder: Long Time No Cont…

The query is practical: what should a introduction email to a Pharmaceuticals Founder say for long time no contact? Start with a direct answer, add one proof point about follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick, and close with ask if the old problem still exists, or if you should leave

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this introduction work for a Pharmaceuticals Founder?

Lead with the overlap, not your résumé.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a founder actually reads: Short, vivid, one proof point max.
Bring a new observation about their world, then offer a small, optional next step.
Make it easy to decline.

When should I send this to a Pharmaceuticals Founder?

If a mutual offered the intro, send it while their permission is fresh. Send when you have a real trigger: news, a useful artifact, a role change, a season. For this combo, treat "Only when you have a trigger" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a founder, Short, vivid, one proof point max. After three touches with different value, send a breakup and archive.

What this Founder actually cares about

A founder in Pharmaceuticals is protecting runway, focus, and the company's early reputation. They context-switch constantly and reply to emails that reduce uncertainty. They can smell a template that was also sent to 400 peers. The hook that earns a look is a problem they personally still own because the team is small. The ask should stay at this size: a yes/no on timing, or a 15-minute working chat. Delete trigger: Calling them a 'decision maker' or pitching like they're a Fortune 500 process. a problem they personally still own because the team is small

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Words that work: MLR, label, access, HCP, congress, promotional review. A thread that ignores follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick reads like every other vendor bump.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone human and specific.
Keep titles accurate. Inflating your role gets checked.
Time it for Only when you have a trigger. Send when you have a real trigger: news, a useful artifact, a role change, a season.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this long time no contact note?

Giant bios make intros feel like homework.
Don't open with 'it's been a while' and then paste the old pitch.
Don't use consumer-startup slang. It's a credibility leak.
Calling them a 'decision maker' or pitching like they're a Fortune 500 process.

How does this long time no contact scenario compare?

Dimension	For this template
Best send window	Only when you have a trigger
Ideal length	Short, vivid, one proof point max.
Primary ask	a yes/no on timing, or a 15-minute working chat
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Human and specific. Peer to peer, not vendor to 'target.'
Unlike no response	This isn't a 4-day bump. It's a re-introduction with a new reason.
Unlike breakup	You're opening a door, not closing one. Still keep it easy to ignore.

What should I copy and send?

Copy-ready template

Subject

[Company Name] / time through MLR

Body

Hi [First Name],

I'll keep this short so you can decide if a conversation is worth it.

In Pharmaceuticals, that usually shows up as follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick. I help [type of company] with cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Recent example: [result] for [similar team]. If that's irrelevant, ignore this.

Re-earn a conversation, not restart a stale sequence at email 4.

Open to a short intro chat, or should I leave this with [Mutual]?

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Name the situation and the business object, not your excitement. Something like "[Company Name] / time through MLR" outperforms "Just checking in" because a founder can decide from the preview text whether it's worth opening. Keep it under 50 characters when you can.

Related templates

Want a custom draft instead? Try the email generator.